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Objective: The aim of this work was to assess the prognostic value of absolute N-terminal-proeB-type
natriuretic peptide (NT-proBNP) concentration in combination with changes during admission because of
acute heart failure (AHF) and early after hospital discharge.
Background: In AHF, readmission and mortality rates are high. Identifying those at highest risk for events
early after hospital discharge might help to select patients in need of intensive outpatient monitoring.
Methods and results: We evaluated the prognostic value of NT-proBNP concentration on admission, at
discharge, 1 month after hospital discharge and change over time in 309 patients included in the PRIMA
(Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity
and mortality?) study. Primary outcome measures were mortality and the combined end point of heart failure
(HF) readmission or mortality. In a multivariate Cox regression analysis, change in NT-proBNP concentration
during admission, change from discharge to 1 month after discharge, and the absolute NT-proBNP concentra-
tion at 1 month after dischargewere of independent prognostic value for both end points (hazard ratios for HF
readmission ormortality: 1.71, 95%confidence interval [CI] 1.13e2.60,Wald 6.4 [P5 .011] versus 2.71, 95%
CI 1.76e4.17, Wald 20.5 [P! .001] versus 1.81, 95% CI 1.13e2.89, Wald 6.1 [P5 .014], respectively.
Conclusions: Knowledge of change in NT-proBNP concentration during admission because of AHF in
combination with change early after discharge and the absolute NT-proBNP concentration at 1 month after
discharge allows accurate risk stratification. (J Cardiac Fail 2014;20:881e890)
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881Acute heart failure (HF) is not only associated with a
high in-hospital mortality rate,1 but short- and long-term
prognosis after hospital discharge also remains poor,
with high mortality and readmission rates.2,3 Therefore,
post-discharge risk stratification is important because it
may help to identify those patients in need of intensive
outpatient monitoring and treatment. Unfortunately, even
for trained clinicians it can be quite challenging to accu-
rately stratify risk in those who have recently been
admitted because of acute HF. During the last decade,
B-type natriuretic peptide (BNP) and its cleavage equiva-
lent N-terminal pro-BNP (NT-proBNP) have proved to be
powerful prognostic markers in both acute and chronic
HF. In acute HF, both pre-discharge (NT-pro)BNP
882 Journal of Cardiac Failure Vol. 20 No. 12 December 2014concentration and decrease in NT-proBNP during hos-
pital admission are related to outcome after hospital
discharge.4,5 Also in chronic HF, not only does a single
measurement of natriuretic peptides reflect risk, but varia-
tion in natriuretic peptides also adds to prognostic
assessment.6
However, the prognostic value of change in NT-proBNP
concentration 1 month after admission because of acute
HF has not yet been evaluated. Furthermore, the incre-
mental value of serial NT-proBNP measurements during
admission and early after hospital discharge has not
yet been assessed. Therefore, we sought to identify
which NT-proBNP parameters during admission and early
after discharge (ie, absolute NT-proBNP concentration at
admission, discharge, 1 month after hospital discharge,
change in NT-proBNP during admission [‘‘inpatient
change’’], and change in NT-proBNP concentration be-
tween discharge and 1 month after discharge [‘‘early
outpatient change’’]) were of independent prognostic
importance. Finally, because biologic variation of NT-
proBNP in HF has been reported to be high in chronic
HF,7 one might conclude that only large early outpatient
changes in NT-proBNP have prognostic impact. There-
fore, we also assessed the prognostic impact of relatively
small early outpatient changes in NT-proBNP (ie, changes
up to 30%).
Methods
Study Design and Study Population
This was a post hoc analysis of patients included in the PRIMA
(Can PRo-brain-natriuretic peptide guided therapy of chronic
heart failure IMprove heart fAilure morbidity and mortality?)
study, a prospective randomized multicenter study assessing the
effect of management of chronic HF guided by individual NT-
proBNP targets.8 Inclusion criteria have been published previ-
ously.8 In short, patients were included during hospital admission
for acute HF. NT-proBNP concentration at admission was required
to be $1,700 pg/mL, and included patients also needed to demon-
strate a decrease in NT-proBNP concentration of at least 10% with
a minimum of 850 pg/mL during admission. At discharge, patients
were randomized to outpatient treatment that was either clinically
guided where NT-proBNP was measured but not revealed to the
physician, or to outpatient treatment where NT-proBNP levels
were provided to guide therapy. The follow-up period was up to
2 years. For the present analysis, patients with outpatient NT-
proBNP concentration available 1 month after hospital discharge
were included. As a result, patients not attending the outpatient
clinic 1 month after discharge (because of death, readmission, or
any other reason) were not included. All events occurring before
the outpatient visit 1 month after hospital discharge were
censored.
Definition of Study End Points
Primary outcome measures were mortality and the combined
end point of HF readmission or mortality within the follow-up
period after the outpatient visit 1 month after discharge. Second-
ary end points encompassed the primary end points reached at
90, 180, and 365 days of follow-up.Statistical Analysis
Data are presented as frequencies, mean 6 SD, or median (in-
terquartile range [IQR]). Comparisons between groups were per-
formed with the use of Fischer exact test for categoric data and
1-way analysis of variance or Kruskal-Wallis H test for continuous
data, as appropriate. Glomerular filtration rate was estimated
(eGFR) with the use of the Modified Diet in Renal Disease
equation.9
Univariate Cox proportional hazard regression analysis was per-
formed to assess clinical covariates associated with mortality.
Spearman rank correlations where used to test correlations among
the various NT-proBNP parameters. Multivariate Cox proportional
hazard regression analysis was performed with the use of all
covariates associated with outcome, except renal function and
NT-proBNP concentration, to assess the clinical model. Variables
were added in a stepwise fashion with P! .05 and P! .1 as the
cutoffs for entry or retention, respectively. After assessment of the
clinical model, renal function (eGFR !30 mL/min, eGFR
30e60 mL/min, or eGFR O60 mL/min) was added to form the
reference model. To assess the independent prognostic value of
NT-proBNP concentration on admission, at discharge, inpatient
change, early outpatient change, and NT-proBNP concentration
at 1 month after hospital discharge, these parameters were added
to the reference model in a stepwise fashion to form the final
NT-proBNP model.
Model accuracy and discrimination were evaluated for both
mortality and the combined end point of HF readmission or mor-
tality within 1 year of follow-up by (i) c-statistic, a measure of the
area under the receiver operating characteristic curve (AUC) and
(ii) integrated discrimination improvement (IDI). Calculations
were done with the use of IBM SPSS Statistics 21.0 (IBM,
Armonk, New York) and Medcalc 13.3.3.0 (Medcalc Software,
Ostend, Belgium).
Composite NT-proBNP Score
Independent predictive NT-proBNP parameters were used to
form the composite NT-proBNP score. This was done by giving
each independent prognostic NT-proBNP parameter 1 point. To
assess the prognostic impact of the composite NT-proBNP
score, 90-, 180, and 365-day mortality and the combined end point
of HF readmission or mortality were calculated for every compos-
ite NT-proBNP score category. Furthermore, Kaplan-Meier sur-
vival curves were assessed and compared with the use of the
log-rank test.
Finally the value of relatively small early outpatient changes in
NT-proBNP (ie, decrease vs increase in NT-proBNP concentration
of !30%) was assessed in a multivariate manner.
Results
Patient Characteristics
In 309 out of 345 patients included in the PRIMA study,
NT-proBNP levels at admission, discharge, and 1 month af-
ter hospital discharge were available. Patient characteristics
at baseline and 1 month after hospital discharge are pre-
sented in Table 1. Patients were overall elderly and predom-
inantly male, more than one-half had coronary artery
disease, and about one-half had an ischemic etiology of
HF. At admission because of acute HF, median NT-
proBNP concentration was clearly elevated, and during
Table 1. Baseline Characteristics of the Overall Population and According to Composite NT-proBNP Score Group
Patient Characteristic
Overall
(n 5 309)
Group 1: 0 Points
(n 5 62)
Group 2: 1 Point
(n 5 94)
Group 3: 2 Points
(n 5 83)
Group 4: 3 Points
(n 5 70)
P Value
(Overall)
Baseline
Age, y 72.0 (12.0) 68.4 (12.2) 70.0 (11.0) 75.1 (12.6) 74.4 (11.2) .001
Female 132 (42.7) 30 (48.4) 39 (41.5) 35 (42.2) 28 (40.0) .782
BMI, kg/m2 25 (4.8) 24.8 (4.7) 25.6 (4.6) 24.1 (4.7) 25.6 (5.2) .213
Hypertension 153 (49.5) 31 (50.0) 50 (53.2) 33 (39.8) 39 (55.7) .191
Diabetes mellitus 86 (27.8) 15 (24.2) 22 (23.4) 20 (24.1) 29 (41.4) .040
Stroke or TIA 55 (17.8) 12 (19.4) 18 (19.1) 14 (16.9) 11 (15.7) .924
Peripheral artery
disease
58 (18.8) 9 (14.5) 20 (21.3) 18 (21.7) 11 (15.7) .571
COPD 53 (17.2) 9 (14.5) 18 (19.1) 14 (16.9) 12 (17.1) .905
Atrial fibrillation 97 (31.4) 14 (22.6) 29 (30.9) 26 (31.3) 28 (40.0) .200
Coronary artery
disease
182 (58.9) 28 (45.2) 49 (52.1) 58 (69.9) 47 (67.1) .005
Myocardial
infarction
124 (40.1) 11 (17.7) 33 (35.1) 43 (51.8) 37 (52.9) !.001
PCI 36 (11.7) 3 (4.8) 13 (13.8) 8 (9.6) 12 (17.1) .130
CABG 54 (17.5) 8 (12.9) 13 (13.8) 16 (19.3) 17 (24.3) .241
Valve replacement 20 (6.5) 1 (1.6) 2 (2.1) 5 (6.0) 12 (17.1) !.001
Pacemaker 28 (9.1) 2 (3.2) 6 (6.4) 9 (10.8) 11 (15.7) .057
ICD 20 (6.5) 1 (1.6) 4 (4.3) 5 (6.0) 10 (14.3) .014
Mitral
regurgitation $II
135 (48.2) 26 (44.1) 42 (48.3) 41 (56.2) 26 (42.6) .391
Previous episode
of HF
108 (35.0) 10 (16.1) 25 (26.6) 31 (37.3) 42 (60.0) !.001
Ischemic cause
of HF
141 (45.8) 17 (27.4) 43 (45.7) 45 (54.2) 36 (52.2) .007
NT-proBNP at
admission, pg/mL
7,897 (4,345e14,030) 7,561 (4,120e12,340) 5,101 (3,234e10,491) 12,280 (6,542e17,597) 8,618 (4,915e15,729) !.001
Discharge
NYHA functional
class $III
67 (21.7) 9 (14.5) 25 (26.6) 17 (20.5) 16 (22.9) .342
Mean arterial
pressure, mm Hg
85.5 (12.9) 88.5 (11.5) 88.4 (13.5) 82.6 (11.0) 82.3 (14.2) .001
Heart rate, beats/min 76.8 (15.6) 77.3 (18.2) 77.4 (15.7) 76.0 (14.8) 76.6 (14.3) .938
QRS duration, ms 112 (94e140) 102 (89e125) 103 (92e128) 116 (100e138) 131 (98e170) .002
LVEF, % 35.9 (14.3) 37.7 (14.0) 36.7 (14.3) 33.6 (13.7) 35.8 (15.4) .381
Hemoglobin,
mmol/L
8.5 (1.2) 8.8 (1.4) 8.8 (1.1) 8.3 (1.2) 8.0 (1.1) .003
Sodium, mmol/L 139.2 (3.5) 139.8 (3.7) 139.6 (3.5) 138.7 (3.0) 138.9 (4.0) .154
Potassium, mmol/L 4.3 (0.5) 4.2 (0.4) 4.3 (0.5) 4.3 (0.4) 4.3 (0.5) .685
Urea, mmol/L 11.7 (8.4e15.9) 9.9 (7.4e12.7) 10.7 (8.2e14.6) 12.6 (8.2e17.2) 14.3 (10.6e19.0) !.001
Creatinine, mmol/L 119 (100e158) 103 (88e124) 114 (98e149) 131 (105e168) 149 (111e209) !.001
eGFR, mL/min 48.1 (33.2e63.9) 60.1 (45.6e69.5) 50.4 (39.3e65.0) 42.9 (31.1e59.5) 39.6 (24.7e54.6) !.001
NT-proBNP, pg/mL 2,936 (1,344e5,505) 1,531 (854e2,544) 1,608 (892e3,847) 4,398 (2,512e6,712) 5,112 (2,873e8,429) !.001
NT-proBNP decrease
during index
hospitalization, %
61.8 (43.2e76.6) 79.4 (69.6e83.9) 66.8 (51.5e79.0) 57.4 (37.6e71.7) 41.5 (29.7e51.2) !.001
Medication at discharge
Diuretics 299 (96.8) 60 (96.8) 90 (95.7) 81 (97.6) 68 (97.1) .945
ACE inhibitors 222 (71.8) 51 (82.3) 68 (72.3) 56 (67.5) 47 (67.1) .182
ARB 60 (19.4) 6 (9.7) 18 (19.1) 20 (24.1) 16 (22.9) .140
Beta-blockers 237 (76.7) 46 (74.2) 76 (80.9) 64 (77.1) 51 (72.9) .631
Aldosterone
antagonists
164 (53.1) 33 (53.2) 44 (46.8) 46 (55.4) 41 (58.6) .477
Digoxin 87 (28.2) 14 (22.6) 33 (35.1) 23 (27.7) 17 (24.3) .289
Outpatient visit at 1 month
Mean arterial
pressure, mm Hg
84.7 (13.6) 89.3 (12.1) 86.4 (13.0) 82.0 (14.7) 81.4 (13.1) .001
Urea, mmol/L 11.0 (8.3e16.7) 8.6 (6.6e11.0) 10.3 (7.2e13.8) 12.5 (8.8e18.0) 14.9 (10.7e22.7) !.001
Creatinine, mmol/8l 130 (100e167) 102 (87e140) 119 (101e148) 133 (105e180) 160 (127e205) !.001
eGFR, mL/min 45.6 (31.6-59.0) 53.6 (42.0e68.6) 51.0 (36.1e63.8) 42.1 (30.2e55.1) 34.9 (26.2e49.8) !.001
Early outpatient
change
NT-proBNP, %
3.5 (34.2 to 46.3) 42.0 (20.8 to 63.9) 7.2 (44.2 to 42.6) 8.0 (15.8 to 54.3) 45.2 (25.1e89.9) !.001
NT-proBNP, pg/mL 2,538 (1,272e5,434) 663 (387e1,360) 1,598 (1,051e2,159) 4,661 (3,052e6,958) 7,614 (4,949e12,928) !.001
NT-proBNP, N-terminal proeB-type natriuretic peptide; BMI, body mass index; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary
disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ICD, implantable cardiac defibrillator; HF, heart failure;
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
Values are expressed as n (%), mean (SD), or median (interquartile range).
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tion was O60%. One month after hospital discharge, me-
dian NT-proBNP concentration was 2,538 pg/mL.
Prediction of Outcome
Median time from hospital discharge to the outpatient visit
1 month after discharge was 30 days (IQR 27e36 days),
with a median follow-up duration of 675 days (IQR
472e700 days) after this visit.
Within the follow-up period, 83 patients died (26.9%)
and 131 patients reached the combined end point of HF re-
admission or mortality (42.4%). Both mortality and the
combined end point at 90, 180, and 365 days in the overall
population are presented in Table 2. In univariate Cox
regression analyses, all NT-proBNP parameters except
NT-proBNP concentration at admission were highly associ-
ated with mortality (Table 3).
Comparison With Patients Not Included in This
Analysis
In 309 of 345 patients, NT-proBNP concentration 1
month after hospital discharge was available. Of the pa-
tients not included for the present analysis, 5 died within
30 days after hospital discharge and 6 had reached the com-
bined end point of HF-related readmission or mortality. Af-
ter exclusion of these patients, there was a trend toward
increased mortality in patients with no NT-proBNP concen-
tration available 1 month after hospital discharge compared
to those with NT-proBNP concentration available (HR 1.75,
95% CI 0.96e3.21; P 5 .070). However, no difference was
seen in combined end point (HR 1.14, 95% CI 0.66e1.97;
P 5 .65).
Correlation Among NT-proBNP Parameters
Correlations among NT-proBNP parameters are de-
picted in Supplemental Table 1. No correlation existed
between inpatient change in NT-proBNP concentration
and early outpatient change (r 5 0.01; P 5 .815).
Modest correlations existed between NT-proBNP con-
centration 1 month after hospital discharge and both
inpatient and early outpatient change in NT-proBNP con-
centration, with strongest correlation being present be-
tween inpatient change and NT-proBNP concentrationTable 2. Mortality and Combined End Point of HF Readmission
composite NT-pro
Outcome Total Group (n 5 309)
Group 1:
0 Points (n 5 62)
Gro
1 Point
Mortality, n (%)
90 days 16 (5.2) 0 (0) 2
180 days 32 (10.4) 0 (0) 5
365 days 55 (17.8) 0 (0) 9
HF-related readmission or mortality, n (%)
90 days 50 (16.2) 1 (1.6) 8
180 days 77 (24.9) 2 (3.2) 14
365 days 103 (33.3) 2 (3.2) 21
Abbreviations as in Table 1.at 1 month follow-up (r 5 0.56; P ! .001). However,
we found strong correlations between the absolute
NT-proBNP concentration at admission, discharge, and
1 month after hospital discharge, with strongest correla-
tion between NT-proBNP at admission and at discharge
(r 5 0.79; P ! .0001).Multivariate Analysis
Based on the multivariate analysis on clinical risk fac-
tors, previous episode of HF, ischemic etiology of HF,
age, and mean arterial pressure (MAP) were included in
the clinical model. In addition, renal function at 1 month af-
ter discharge (eGFR !30 mL/min, 30e60 mL/min, or
O60 mL/min) was added to form the reference model.
Adding eGFR as a continuous instead of a categoric vari-
able did not change the predictive performance of the refer-
ence model.
When adding the NT-proBNP parameters to this
reference model, inpatient change in NT-proBNP concen-
tration (decrease below vs above the median), early out-
patient change in NT-proBNP (increase vs decrease),
and NT-proBNP concentration at 1 month after discharge
(above vs below the median) remained independent prog-
nostic markers, whereas the absolute NT-proBNP concen-
tration at discharge dropped out of the model (Table 3).
The final NT-proBNP prognostic model therefore con-
sisted of the reference model plus inpatient change in
NT-proBNP concentration, early outpatient change in
NT-proBNP, and the absolute NT-proBNP concentration 1
month after discharge.
Model accuracy and discrimination of the NT-proBNP
prognostic model for 1-year mortality and 1-year HF read-
mission or mortality are presented in Table 4. Model accu-
racy and discrimination for HF readmission and mortality
reached a c-statistic of 0.85 (95% CI 0.81e0.90), with
excellent calibration (Hosmer-Lemeshow: P 5 .77), and
had significantly better model performance than models
with 1 NT-proBNP parameter (IDI ranging from 6% to
13% [P ! .001], improvement in c-statistic ranging from
0.3 to 0.7 [P! .05]; Table 4). For mortality, the same trend
was seen (Table 4).or Mortality of the Overall Population and According to the
BNP Score
up 2:
(n 5 94)
Group 3:
2 Points (n 5 83)
Group 4:
3 Points (n 5 70) P Value
(2.1) 4 (4.8) 10 (14.3) .001
(5.3) 10 (12.0) 17 (24.3) !.001
(9.6) 17 (20.5) 29 (41.4) !.001
(8.5) 14 (16.9) 27 (38.6) !.001
(14.9) 21 (25.3) 40 (57.1) !.001
(22.3) 27 (32.5) 53 (75.7) !.001
Table 3. Univariate and Adjusted Multivariate Hazard Ratios for Predictors of Mortality and for the Composite End Point of HF
Readmission or Mortality
Univariate Analysis Adjusted Multivariate Analysis*
HR 95% CI Wald P Value HR 95% CI Wald P Value
Mortality
NT-proBNP at admission above
versus below the median
1.33 0.86e2.05 1.7 .197
Inpatient decrease NT-proBNP
below vs above the median
3.07 1.90e4.98 20.9 !.001 1.72 1.01e2.91 4.0 .045
NT-proBNP at discharge above vs
below the median
2.52 1.58e4.00 15.2 !.001
Early outpatient increase vs
decrease in NT-proBNP
4.94 2.90e8.43 34.4 !.001 1.88 1.12e3.16 5.6 .018
NT-proBNP at 1 month above vs
below the median
2.61 1.62e4.19 15.6 !.001 2.09 1.10e3.97 5.1 .024
HF readmission or mortality
NT-proBNP at admission above
versus below the median
1.23 0.87e1.73 1.4 .242
Inpatient decrease NT-proBNP
below vs above the median
2.34 1.64e3.36 21.6 !.001 1.71 1.13e2.60 6.4 .011
NT-proBNP at discharge above vs
below the median
1.71 1.21e2.43 9.2 .002
Early outpatient increase vs
decrease in NT-proBNP
3.31 2.25e4.86 37.1 !.001 2.71 1.76e4.17 20.5 !.001
NT-proBNP at 1 month above vs
below the median
3.41 2.34e4.98 40.3 !.001 1.81 1.13e2.89 6.1 .014
HR, hazard ratio; CI, confidence interval; other abbreviations as in Table 1.
Hazard ratios calculated within the total follow-up period.
*Adjusted for clinical parameters.
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By combining the independent prognostic NT-proBNP
parameters (ie, inpatient decrease in NT-proBNP concentra-
tion below vs above the median, early outpatient increase vsTable 4. Performance of Predictive Models for 1-Year Mortality a
Model
Mortality
Clinical risk factorsy
+ Inpatient change in NT-proBNP
+ Early outpatient change in NT-proBNP
+ NT-proBNP at 1 month follow-up
Clinical risk factorsy + inpatient change in NT-proBNP
+ Early outpatient change NT-proBNP + NT-proBNP at 1 month
Clinical risk factorsy + early outpatient change in NT-proBNP
+ Inpatient change in NT-proBNP + NT-proBNP at 1 month
Clinical risk factorsy + NT-proBNP at 1 month
+ Inpatient change in NT-proBNP + early outpatient change in NT-proBNP
HF-related readmission or mortality
Clinical risk factorsy
+ Inpatient change in NT-proBNP
+ Early outpatient change in NT-proBNP
+ NT-proBNP at 1 month follow-up
Clinical risk factorsy + inpatient change in NT-proBNP
+ Early outpatient change in NT-proBNP + NT-proBNP at 1 month
Clinical risk factorsy + early outpatient change NT-proBNP
+ Inpatient change in NT-proBNP + NT-proBNP at 1 month
Clinical risk factorsy + NT-proBNP at 1 month
+ Inpatient change in NT-proBNP + early outpatient change in NT-proBNP
AUC, area under the receiver operating characteristic curve; IDI, integrated dis
Tables 1 and 3.
*For the Hosmer-Lemeshow statistic, a P value close to 1 indicates excellent
yReference model including previous episode of HF, ischemic etiology of HF
z! 0.1.
x!0.05.
jj!.01.
#!.001.decrease in NT-proBNP, and NT-proBNP concentration at 1
month after discharge above vs below the median), a com-
posite NT-proBNP score was formed by giving 1 point for
each parameter that was elevated. This resulted in patientsnd the Combined End Point of HF Readmission or Mortality
c2 Model c-Statistic: AUC (95% CI) IDI Hos-Lem*
45.0 0.77 (0.71e0.84) .833
50.3x 0.79 (0.72e0.85) 2%z .924
53.7jj 0.80 (0.74e0.86)z 3%x .472
57.0jj 0.80 (0.74e0.87)z 4%# .806
50.3 0.79 (0.72e0.85) .924
64.1 0.82 (0.77e0.88)x 5%# .461
53.7 0.80 (0.74e0.86) .472
64.1jj 0.82 (0.77e0.88) 4%jj .461
57.0 0.80 (0.74e0.87) .806
64.1x 0.82 (0.77e0.88) 2%z .461
60.7 0.76 (0.70e0.82) .225
72.2# 0.78 (0.73e0.84) 3%jj .475
96.9# 0.82 (0.77e0.87)jj 10%# .523
83.4# 0.81 (0.76e0.86)x 7%# .365
72.2 0.78 (0.73e0.84) .475
117.1# 0.85 (0.81e0.90)# 13%# .773
96.9 0.82 (0.77e0.87) .523
117.1# 0.85 (0.81e0.90)x 6%# .773
83.4 0.81 (0.76e0.86) .365
117.1# 0.85 (0.81e0.90)jj 9%# .773
crimination index, Hos-Lem, Hosmer-Lemeshow; other abbreviations as in
calibration.
, age, mean arterial pressure, and eGFR.
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(group 1) to 3 parameters elevated (group 4). Baseline char-
acteristics of all groups are depicted in Table 1. With
increasing NT-proBNP parameters elevated, patients were
older, more often had a previous episode of heart failure,
and more often had ischemic cause of HF. Increasing com-
posite NT-proBNP score was also associated with lower
blood pressure and more impaired renal function. Interest-
ingly left ventricular ejection fraction did not differ among
the 4 groups.
The composite NT-proBNP score strongly predicted
events: both short- and long-term prognosis differed signifi-
cantly among the 4 groups regarding mortality and the com-
bined end point HF-related readmission or mortality
(Table 2; Fig. 1). All patients without NT-proBNP
parameters elevated (group 1; n 5 62) survived 1 year
follow-up, whereas 41% of patients with all 3 NT-proBNP
parameters elevated (group 4; n 5 70) died within 1 year
of follow-up.Prognostic Impact of Small Outpatient Changes in
NT-proBNP Concentration
Small changes in NT-proBNP concentration are associ-
ated with outcome. In multivariate analysis including the
reference model, inpatient change in NT-proBNP, and
NT-proBNP concentration at 1 month after discharge, early
outpatient increase in NT-proBNP concentration !30%
was associated with worse outcome compared with early
outpatient decrease in NT-proBNP !30% (HR for mortal-
ity 2.05, 95% CI 1.02e4.13, Wald 4.1 [P5 .04], HR for the
combined end point 2.59, 95% CI 1.45e4.64, Wald 10.2
[P 5 .001]). Interestingly, there was no significant differ-
ence in mortality or the combined end point between
patients with an early outpatient decrease of !30% vs
O30% (HR for the combined end point 1.04, 95% CI
0.50e2.18, Wald 0.01; P 5 .914). Likewise, an increase
in NTproBNP concentration of !30% yielded a clinically
similar hazard for events compared with an increaseO30%
(HR for the combined end point 0.96, 95% CI 0.62e1.47,
Wald 0.04; P 5 .837).Prognostic Value of NT-proBNP Parameters in Both
Treatment Arms of the PRIMA Study
Because in one-half of the patients included in the
PRIMA-study the treating physician was not blinded to
the outpatient NT-proBNP concentration, knowledge of
NT-proBNP might have influenced the decision whether
to admit a patient or not. However, in multivariate analysis
correcting for the reference model and randomization
group, inpatient change in NT-proBNP, early outpatient
change in NT-proBNP, and NT-proBNP concentration 1
month after hospital discharge remained independent prog-
nostic factors (Supplemental Table 2). Moreover, in both
treatment arms all 3 NT-proBNP parameters were of prog-
nostic importance (Supplemental Figs. 1 and 2).Discussion
In this study, we evaluated the prognostic value of serial
NT-proBNP measurements during and early after an admis-
sion for acute HF. We demonstrated that the a) inpatient
change in NT-proBNP concentration, b) early outpatient
change, and c) absolute NT-proBNP concentration at 1
month after discharge were each independent prognostica-
tors and together enabled accurate short- and long-term
outpatient risk assessment. Importantly, even small changes
in the early outpatient phase (ie, !30% change in
NT-proBNP) had prognostic meaning.Inpatient NT-proBNP Measurements
Although the natriuretic peptide concentration at ad-
mission for acute HF predicts inpatient mortality,10 its prog-
nostic effect after discharge seems to be small. This is in
sharp contrast to NT-proBNP concentration at discharge
and changes in NT-proBNP during admission, which both
seem to be better predictors of outcome. For example, Bet-
tencourt et al4 demonstrated that a NT-proBNP level
O6,779 pg/mL at hospital admission predicted a nonsignif-
icant trend toward hazard of readmission or death, but the
NT-proBNP concentration at discharge of 4,137 pg/mL
was a much stronger predictor of hazard (log rank P
for cumulative hospitalization-free survival: !.001). They
furthermore found that inpatient decrease in NT-proBNP
values of $30% was related to favorable outcome. In addi-
tion, Kubler et al11 demonstrated that the optimal cutoff
value for inpatient decrease in NT-proBNP was 65%. A
decrease in NT-proBNP concentration in acutely decompen-
sated HF is related to hemodynamic improvement12 and is
thereby a marker of success of HF treatment during admis-
sion. It is therefore not surprising that the extent of decrease
in NT-proBNP during admission reflects outpatient outcome
after discharge. Our findings go beyond these conclusions,
showing that inpatient changes in NT-proBNP are of prog-
nostic importance independently from early outpatient
changes as well as independently from NT-proBNP levels
measured at 1 month after hospital discharge.
In contrast to inpatient change in NT-proBNP,
NT-proBNP concentration at discharge failed to retain
prognostic impact in multivariate analysis.
The presence of strong correlations between the absolute
NT-proBNP concentrations will certainly have influenced
the selection process in multivariate analysis that led to
the uptake of NT-proBNP concentration at 1 month after
hospital discharge over NT-proBNP at hospital discharge
(Supplemental Table 2). However, the fact that NT-
proBNP concentration 1 month after hospital discharge re-
mained the strongest prognostic NT-proBNP value is not
surprising, because it is the most recent measurement.
This is also shown by univariate analysis: NT-proBNP
concentration 1 month after hospital discharge yielded
the highest Wald score for mortality (15.6 vs 15.2 for
NT-proBNP at discharge).
Fig. 1. Kaplan-Meier curve for (A) mortality and (B) the combined end point of HF hospitalizationefree survival according to the
composite N-terminal proeB-type natriuretic peptide (NT-proBNP) score.
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The prognostic value of changes in NT-proBNP at the
outpatient clinic compared with only a single measurement
seems to depend on the outpatient setting. One study re-
ported that absolute NT-proBNP concentration at 3 months
after acute HF admission had more predictive power in
multivariate analysis than percentage change within
3 months (chi-square value of log NT-proBNP after
3 months 41.5, compared with 7.5 for NT-proBNP percent-
age change).13
Also in chronic stable HF, the prognostic power of abso-
lute NT-proBNP concentration appears to be superior to
relative changes in NT-proBNP. A subanalysis of the Val-
HeFT trial, for example, demonstrated a higher prognostic
discrimination of a single determination of NT-proBNP
compared with relative changes after 4-month follow-up
(AUC 0.70 vs 0.60, respectively).6
Changes in NT-proBNP concentration seem to have
higher prognostic impact in outpatient destabilized HF;
Bayes-Genis et al, for example, reported a 21% reduction
in events for every 10% decrease in NT-proBNP within
2 weeks.14 In contrast, the absolute NT-proBNP concentra-
tion at 2 weeks lost its predictive power in multivariate
analysis.
We show that 1 month after hospital discharge, change in
NT-proBNP has prognostic power similar to the absolute
NT-proBNP concentration measured at 1 month for predic-
tion of mortality (Table 3). For prediction of the combined
end point of HF readmission or mortality, early outpatient
change in NT-proBNP is clearly superior to the absolute
concentration at 1 month (Wald 20.5 vs 6.1, respectively;
Table 4). Thus it seems that in patients at highest risk for
events (outpatient destabilized HF and early after admission
because of acute HF), a change in NT-proBNP concentra-
tion between 2 measurements at relatively short interval
is an important predictor for events, and clinical stability
cannot be assumed by only 1 NT-proBNP measurement.Prognostic Importance of Small Changes in NT-
proBNP Concentration 1 Month After Hospital
Discharge
Changes in natriuretic peptide concentrations may reflect
changes in cardiac wall stress and cardiac performance, but
may also depend on the biologic variability of these bio-
markers. For NT-proBNP, biologic variability has been as-
sessed in chronic HF patients at different time intervals
(within-day, week-to-week, 1 to 3 months, and year-to
year7,15e19). Short term biologic variability in terms of
reference change values (RCVs) differed widely among
studies published, varying from 23%19 to 98%,7 suggesting
that changes in NT-proBNP concentration even up to 100%
may be safely accepted. Our finding that small changes in
NT-proBNP concentration (ie, !30%) early after hospital
discharge are of prognostic importance challenges these
interpretations of so-called ‘‘biologic variability’’ of NT-
proBNP. The high RCVs found in the previously mentionedstudies are controversial because they appear to be related
to the skewed distribution of measured NT-proBNP values
and improve after normalizing transformation of the data.16
Also, median NT-proBNP concentrations in studies assess-
ing biologic variability of NT-proBNP were relatively low
(579e1,323 pg/mL)15,16 and biologic variability has been
shown to decrease with elevating NT-proBNP concen-
tration.15 Furthermore patient numbers were limited in
these studies (20e78 patients).18,19 Most importantly, these
studies assumed that their patients were in a stable condi-
tion based on clinical characteristics and on their stability
in the past, but did not take into account the long-term sur-
vival after measurement of NT-proBNP concentration.
Moreover, it was assumed that clinical stability can easily
be assessed without in-depth diagnostic testing, which is
most likely not the case. Therefore, objective evidence of
clinical stability was lacking and subclinical changes in
NT-proBNP concentration might have actually been an
earlydsubclinicaldsign of worsening HF. Indeed, in line
with this reasoning, the only study assessing short term bio-
logic variability of NT-proBNP with a follow-up period of
6 months showed the lowest RVC, 23%.19
Composite NT-proBNP Score and Implications for
Clinical Practice
A composite NT-proBNP score that combines inpatient
change in NT-proBNP with early outpatient change and
the absolute NT-proBNP concentration 1 month after hospi-
tal discharge identified HF patients at very low (1.6%), in-
termediate (8.5%e16.9%), and high (38.6%) risk for early
readmission or mortality. The prognostic impact remained
after one year follow-up. The composite NT-proBNP score
has been designed to illustrate the incremental information
from the different NT-proBNP measurements. Because the
cutpoints for the NTproBNP parameters were defined by
the distribution within the PRIMA study, application of
these cutpoints cannot be used in clinical practice until vali-
dation analysis has been performed. Furthermore, whether
knowledge of the individual risk for events would lead to
reduction in morbidity and mortality remains to be assessed
by future trials and cannot be answered by the present
study. However, it seems plausible that patients at highest
risk for events might benefit most from intensified outpa-
tient follow-up in combination with increased prescription
of evidence-based HF medication, such as angiotensin-
converting enzyme inhibitors, beta-blockers, and aldoste-
rone antagonists.
Recent trials assessing the effect of natriuretic peptidee
guided therapy in HF that randomized patients into 3
treatment arms (ie, regular outpatient care vs intensified
outpatient care with or without knowledge of natriuretic
peptide concentration) have shown that intensified outpa-
tient care leads to a decrease in HF related readmissions
and mortality compared to usual care.20,21 The BATTLE-
SCARRED (NT-proBNPeAssisted Treatment to Lessen
Serial Cardiac Readmissions and Death) trial, eg, demon-
strated 1-year mortality being lower in the intensified
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outpatient treatment group (9.1%) compared with usual care
(18.9%; P 5 .03).21 Furthermore, in all 4 studies demon-
strating a positive effect of natriuretic peptideeguided
therapy,20,22e24 a marked increase in evidence-based HF
medication was seen in the natriuretic peptideeguided arm
compared with the usual care arm. Thus, intensified treat-
ment in combination with increase in evidence-based HF
medication appears to lead to better outcome. In 2 of these
4 trials, patients allocated to the NT-proBNPeguided ther-
apy arm had fewer prescription of loop diuretics compared
with usual care management.20,22 In the PRIMA study,
which failed to demonstrate a significant reduction in end
points by NT-proBNPeguided therapy, outpatient elevated
NT-proBNP levels led most frequently to an increase in
diuretic dosage (O40%).8
Given the association between loop diuretics and
worsening of renal function, neurohumoral activation, and
adverse outcome in HF,25 the use of diuretics is recommen-
ded to be limited to achieve and maintain an euvolemic
state with the lowest achievable dose.26
Combining individual risk assessment with the previ-
ously mentioned findings from the recent natriuretic
peptideeguided therapy studies might lead to an early
outpatient individual treatment approach that should be
confirmed in future trials. It is assumed that if individual
risk for events is low (ie, low composite NT-proBNP score)
and a patient is clinically euvolemic, then diuretic dosage
should be lowered and outpatient follow-up might be
directed to the primary care. If individual risk is high (ie,
high composite NT-proBNP score) and the patient is clini-
cally euvolemic, then outpatient follow-up should be inten-
sified at a dedicated outpatient HF clinic with extra
attention being paid to compliance and intensified prescrip-
tion of evidence-based HF medication. If clinical signs of
overt or worsening HF occur, diuretic dosage should be
increased first, followed by intensification of evidence-
based HF medication. However, as already said, large ran-
domized trials are needed to further clarify this issue.Study Limitations
There are some limitations to the present study. It should
be emphasized that the composite NT-proBNP score was
calculated to visualize the incremental value of serial NT-
proBNP measurements during and early after admission
because of acute HF. It was not the intention to develop a
risk score that can be used in clinical practice. The NT-
proBNP cutpoints were defined from patients included in
the PRIMA study. To be included in the PRIMA study,
NT-proBNP concentration during admission needed to
decrease $10% with a minimum of 850 pg/mL. Therefore,
we cannot extrapolate our results to patients with a smaller
decrease, or an increase in NT-proBNP concentration, dur-
ing admission. Also, as this study is a post hoc analysis, re-
sults remain to be validated by another, preferably larger,
prospective study.Conclusion
For adequate individual risk assessment early after hospi-
tal discharge, knowledge of serial NT-proBNP values is
important. Early changes in NT-proBNP concentration after
admission because of HF, the extent of decrease in NT-
proBNP concentration during admission and the absolute
NT-proBNP concentration 1 month after hospital discharge
are independent prognostic parameters. They may help to
further individualize risk of readmission because of HF or
mortality. Even relative small early outpatient changes in
NT-proBNP are associated with outcome, suggesting that
biologic variability is small and that changes in these levels
do reflect underlying pathophysiologic processes. Knowl-
edge of individual risk might lead to an individualized treat-
ment approach, and the effect of such an approach should
be assessed in future randomized trials.
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